Company intelligence / Profile preview
Rege Nephro Co., Ltd.
Kyoto-shi/Sakyo-ku, Kyoto, Japanregenephro.co.jp ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Rege Nephro is a clinical-stage biotech company developing therapies for kidney diseases, notably ADPKD and CKD. Its lead program, RN-014 (tamibarotene), a RAR agonist, is in Phase 2 trials in Japan with preliminary efficacy and no significant safety concerns reported. The company also develops an iPSC-derived nephron progenitor cell therapy for CKD, which has shown efficacy in animal models and is advancing toward clinical trials[7][8].
- Therapeutic areas
- Nephrology
- Modalities
- Small moleculesCell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
NIKKISO CO., LTD. – scale-up manufacturing collaboration[2]Mitsui Chemicals, Inc. – strategic investor and collaborator[6]Fujifilm – collaborative research on human kidney chip technology[10]
Beyond the preview
Go deeper on Rege Nephro Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rege Nephro Co., Ltd..